Promega UK’s 6th Biologics Symposium includes US R&D and industry speakers

The line-up of speakers includes representatives from GSK and AstraZeneca

13 Sept 2022
Blake Forman
Content Creator

Promega UK the Life Sciences Company, based on the University of Southampton Science Park in Hampshire, is proud to be hosting its 6th Biologics Symposium at The Royal College of Surgeons, London on Thursday 22nd September 2022.

The day is already attracting leading researchers with an interest in biologics to the Symposium. Researchers attending come from a mixture of pharma and biotechnology companies as well as from the academic arena.

This year the line-up of speakers will include representatives from GSK and AstraZeneca, who will be discussing their latest research and innovation in biotherapeutics.

The Biologics Symposium will also give those attending the opportunity to hear about new tools being developed in Promega R&D to help the development of biologic therapeutics, including monoclonal antibodies, cell therapy, and gene therapy.

There will also be dedicated time for networking with fellow researchers in the biologics field as this event is once again being held in person.

Interest in this free-to-attend event is always high - registration is now open.

Want the latest science news straight to your inbox? Become a SelectScience member for free today>>

ONE-Glo + Tox Luciferase Reporter and Cell Viability Assay

Promega Corp.

The ONE-Glo™ + Tox Assay combines luciferase assay chemistry with a cell viability marker to better understand reporter gene expression in the context of cell health. The assay uses a two-step, addition-only process to make these measurements in a single well of a plate, negating the need to run parallel assays. The first part of the assay is a nonlytic fluorescence assay (CellTiter-Fluor™ Cell Viability Assay) that measures the relative number of live cells in a culture population after experimental manipulation. The CellTiter-Fluor™ Assay measures a conserved and constitutive protease activity within live cells and therefore serves as a marker of cell viability. The live-cell protease activity is restricted to intact viable cells and is measured using a fluorogenic, cell-permeant peptide substrate (glycylphenylalanyl-aminofluorocoumarin; GF-AFC). The substrate enters intact cells where it is cleaved by the live-cell protease to generate a fluorescent signal proportional to the number of living cells (Figure 1). This live-cell protease becomes inactive upon loss of cell membrane integrity and leakage into the surrounding culture medium. Fluorescence of the free AFC fluorophore is measured with a microplate reader or CCD imager using an excitation wavelength of 380–400nm and emission wavelength of 505nm. The second part of the assay uses the ONE-Glo™ Luciferase Assay System to quantify firefly luciferase reporter gene expression from cells made to express this reporter enzyme (Figure 2). The ONE-Glo™ Luciferase Assay Buffer and ONE-Glo™ Luciferase Assay Substrate, provided with this system, are combined to form the ONE-Glo™ Reagent. Ideally suited for high- and ultrahigh-throughput applications, the ONE-Glo™ Assay contains a new fluoroluciferin substrate, resulting in a reagent that is more stable, more tolerant to sample components, and has less odor than standard luciferase assay reagents. Luminescence is measured with a microplate reader or CCD imager. Features - Benefits • Efficient: Measure cell viability and firefly luciferase gene expression within the same assay well. • Acquire more data by performing two measurements on cells in a single assay well. • Better Biology: Understand reporter gene expression in the context of cell viability. • Easy to Perform: The assay uses a simple sequential “add-mix-read” format (Figure 3). • Flexible and Automation-Friendly: The volumes of each assay component can be scaled to meet throughput needs and is amenable to automation up to 1,536-well format.

(0)

Links

Tags

Promega UK’s 6th Biologics Symposium includes US R&D and industry speakers